edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: Sareum Holdings
Sareum is a UK-based drug development company, specialising in small molecule kinase inhibitors. Its flagship programmes are its pre-clinical TYK2/JAK1 inhibitors, SDC-1801 for autoimmune diseases and SDC-1802 for cancer. SDC-1801 is undergoing advanced dose finding and toxicology studies with a target to file a CTA in mid-2021. Other programmes include the CHK1 inhibitor SRA737 (Sareum holds a 27.5% economic interest), previously out licensed to Sierra Oncology and the de-prioritised FLT3+Aurora kinase.
Sareum Holdings — 1 video in collection
Sareum Holdings (AIM: SAR) is a UK-listed drug-discovery company focused on the development of small molecule kinase inhibitors. Its in-house programmes are dual TYK2/JAK1 inhibitors: SDC-1801 for autoimmune diseases and SDC-1802 for cancer. The third development programme is SRA737, a CHK1 inhibitor targeting the DNA damage response network for the treatment of solid tumours. Sareum holds a 27.5% economic interest in SRA737.
Listen on your preferred podcast player below:
About Bull, Bear & Beyond: Each episode features candid conversations with senior executives and from our own team of experts from across industries, exploring strategy, innovation, and the opportunities shaping their markets and 60-second pieces are a compressed summary of content designed to convey our message in a single, easily shareable hit.
Get access to the very latest content matched to your personal investment style.